Short Communication

Revolutionary Immunotherapy for Merkel Cell Carcinoma: Retifanlimab-Dlwr (Zynyz) Receives FDA Approval

Abstract

• Approval of Retifanlimab-dlwr (brand name Zynyz) represents a significant breakthrough in the field of dermatology, providing a promising treatment option for patients diagnosed with this highly aggressive and rare form of Merkel Cell Carcinoma (MCC). Traditionally, treatment options for MCC have been limited, with surgery, radiation, and chemotherapy are the mainstays. Retifanlimab-dlwr debut will mark a milestone in the treatment of MCC. Clinical trials have shown impressive results, with a significant number of patients experiencing durable responses to the therapy. Retifanlimab-dlwr is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1), which is expressed on immune cells and helps to reactivate the body's immune response against cancer cells. The impending use of Retifanlimab-dlwr not only provides a groundbreaking treatment option for MCC but also paves the way for further advancements in immunotherapy and personalized medicine.
  
  

• Keywords: Immunotherapy, merkel cell carcinoma, retifanlimab-dlwr, skin cancer.

• DOI:  https://doi.org/10.37184/lnjcc.2789-0112.5.4

Back to All Articles